Kinneret Savitsky - Evogene Independent Director

EVGN Stock  ILA 241.10  15.70  6.11%   

Director

Dr. Kinneret Livnat Savitsky serves as Independent Director at Evogene Ltd since September 17, 2010. She is a member of the Audit, Compensation, Nominating and Corporationrationrate Development committees. Dr. Livnat Savitsky work experience includes the following roles Director at Compugen Ltd, Vice President Biology, Research Development at Compugen Ltd, Interim Chief Executive Officer and Board Member of FutuRx Ltd, Director at various companies, Consultant and Chief Executive Officer at BioLineRx Ltd since 2010.
Age 50
Tenure 14 years
Phone(972) 8 946 6724
Webwww.evogene.com
Livnat Savitsky holds a BS degree in Biochemistry from Tel Aviv University, a BS degree in Biology from The Hebrew University of Jerusalem and a MS degree and a Doctorate of Science degree, both in Human Genetics from Tel Aviv University.

Evogene Management Efficiency

The company has return on total asset (ROA) of (0.2789) % which means that it has lost $0.2789 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6255) %, meaning that it generated substantial loss on money invested by shareholders. Evogene's management efficiency ratios could be used to measure how well Evogene manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 2.39 M in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Evogene has a current ratio of 12.49, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Evogene until it has trouble settling it off, either with new capital or with free cash flow. So, Evogene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Evogene sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Evogene to invest in growth at high rates of return. When we think about Evogene's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

David GranotBezeq Israeli Telecommunication
71
Ehud MezumanBezeq Israeli Telecommunication
62
Haggai HermanBezeq Israeli Telecommunication
51
Orna PeledBezeq Israeli Telecommunication
45
Tali SimonBezeq Israeli Telecommunication
48
Shlomo RodavBezeq Israeli Telecommunication
67
Gilead HalevyCompugen
51
Dov KotlerBezeq Israeli Telecommunication
60
Ilan BiranBezeq Israeli Telecommunication
70
Sanford ZweifachCompugen
60
Doron TurgemanBezeq Israeli Telecommunication
49
Mordechai KeretBezeq Israeli Telecommunication
60
Yair AharonowitzCompugen
73
Eldad MosheBezeq Israeli Telecommunication
50
Joshua ShemerCompugen
63
Amikam ShorerBezeq Israeli Telecommunication
49
Edith LuskyBezeq Israeli Telecommunication
66
Amnon DickBezeq Israeli Telecommunication
64
Ruth ArnonCompugen
86
Ami BarlevBezeq Israeli Telecommunication
39
Ytzhak EdelmanBezeq Israeli Telecommunication
64
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. EVOGENE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 131 people. Evogene (EVGN) is traded on Tel Aviv Stock Exchange in Israel and employs 133 people.

Management Performance

Evogene Leadership Team

Elected by the shareholders, the Evogene's board of directors comprises two types of representatives: Evogene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evogene. The board's role is to monitor Evogene's management team and ensure that shareholders' interests are well served. Evogene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evogene's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mark Kapel, Executive Vice President-Technology
Assaf Oron, Executive VP Corporate Devel.
Martin Gerstel, Chairman of the Board
Oded Shoseyov, Director
Eyal Leibovitz, CFO
Yaron Eldad, Chief Officer
Eyal Ronen, Exec Devel
Adina Makover, Independent Director
Adrian Percy, Director
Sarit Firon, Independent Director
Sassi Masliah, Exec Devel
Yuval BenGalim, COO
Michael Anghel, External Director
Liat Wejgman, VP HR
Eran Kosover, Executive Vice President & General Manager Ag-Chemicals
Ofer CPA, CEO Pres
Ofer Haviv, President, Chief Executive Officer
Amos Shachar, Vice President of Project Management
Ido Dor, Executive Vice President & General Manager Ag-Biologicals
Sigal Fattal, Executive Officer
Dotan Borenstein, Chief Ltd
Nir Arbel, Chief Officer
Hagai Karchi, Chief Technology Officer & Head of R&D Ag-Biologicals
Leon Recanati, Independent Director
Alin SelaBrown, Vice President Screening & Validation Systems
Kinneret Savitsky, Independent Director
Eli Zangvil, Director
Eyal Emmanuel, Executive Vice President-R&D
Assaf Kacen, Chief Operation Officer
Arnon Heyman, Vice President & General Manager of Ag-Seeds
Kinneret Savitzky, External Director
Simcha Sadan, Director
Alex Taskar, Chief Financial Officer
Lea Bloom, Director of Administration & Human Resources
Ziv Kop, Independent Director
Elran MBA, Chief Ltd

Evogene Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evogene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Evogene in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Evogene's short interest history, or implied volatility extrapolated from Evogene options trading.

Pair Trading with Evogene

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Evogene Stock refer to our How to Trade Evogene Stock guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Evogene Stock analysis

When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.